The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A novel microbial-derived peptide therapeutic vaccine (EO2463) as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent non-Hodgkin lymphoma (SIDNEY).
 
Pier Luigi Zinzani
Consulting or Advisory Role - ADC Therapeutics; BeiGene; Bristol-Myers Squibb; Celltrion; EUSA Pharma; Gilead Sciences; Incyte; Janssen-Cilag; Kyowa Hakko Kirin; MSD; Novartis; Roche; Sandoz; Secura BIO; SERVIER; Takeda; TG Therapeutics
Speakers' Bureau - EUSA Pharma; MSD; Novartis
 
Stephen M. Ansell
Honoraria - Research to Practice; WebMD
Research Funding - ADC Therapeutics (Inst); Affimed Therapeutics (Inst); AI Therapeutics (Inst); Bristol-Myers Squibb (Inst); Regeneron (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
 
Francesc Bosch
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Janssen-Cilag; Kite, a Gilead company; Lilly; Novartis; Roche/Genentech
Speakers' Bureau - Abbvie; AstraZeneca; Janssen; Roche
Research Funding - AstraZeneca; Janssen
 
Jonathan W. Friedberg
Research Funding - Enterome (Inst)
Patents, Royalties, Other Intellectual Property - Patient on bone marrow microenvironment signals (I)
 
Jean pierre Marolleau
No Relationships to Disclose
 
Luca Arcaini
Consulting or Advisory Role - ADC Therapeutics; Celgene/Bristol-Myers Squibb; EUSA Pharma; Incyte; Janssen-Cilag; Kite/Gilead; Roche; Verastem
Speakers' Bureau - EUSA Pharma; Novartis
Research Funding - Gilead Sciences
Travel, Accommodations, Expenses - Celgene; Eusa Pharma; Janssen-Cilag; Roche
 
Ramón Garcia-Sanz
Honoraria - Amgen; Astellas Pharma; Beigene; Janssen; Novartis; Takeda
Consulting or Advisory Role - Janssen
Research Funding - Astellas Pharma; Gilead Sciences (Inst); Incyte (Inst)
Patents, Royalties, Other Intellectual Property - BIOMED 2 primers (Inst)
Travel, Accommodations, Expenses - Janssen; Takeda (I)
Other Relationship - Spanish Society of Hematology
 
Ajay K. Gopal
Honoraria - Actinium Pharmaceuticals; ADC Therapeutics; Amgen; Cellectar; Epizyme; Gilead Sciences; I-mab; Janssen Oncology; Kite/Gilead; Merck; morphosys; nurix; Pfizer; Seagen; Takeda; TG Therapeutics
Consulting or Advisory Role - Cellectar; Gilead Sciences; I-Mab; Incyte; Janssen Oncology; Kite/Gilead; Millennium; morphosys; nurix; Pfizer; Seagen; TG Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); I-Mab (Inst); IgM (Inst); Janssen Oncology (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst); Seagen (Inst); Takeda (Inst); Teva (Inst)
 
Carlos Grande
No Relationships to Disclose
 
Reid Merryman
Consulting or Advisory Role - Adaptive Biotechnologies; Bristol-Myers Squibb/Medarex; Genmab
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche (Inst); Genmab (Inst); Merck (Inst)
 
Antonio Pinto
No Relationships to Disclose
 
Stephen D. Smith
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca; BeiGene; Incyte; Karyopharm Therapeutics; Kite/Gilead; Takeda
Research Funding - Acerta Pharma/AstraZeneca (Inst); Ayala Pharmaceuticals (I); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (I); De Novo Pharmaceuticals (Inst); Genentech/Roche (Inst); Ignyta (I); Incyte (Inst); Merck Sharp & Dohme (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Seagen (Inst)
 
Jose Caetano Villasboas
Consulting or Advisory Role - Curio Science (Inst); Kite/Gilead (Inst); Regeneron (Inst); TG Therapeutics (Inst)
Research Funding - Aptose Biosciences (Inst); Enterome (Inst); Epizyme (Inst); Regeneron (Inst)
 
Danielle Wallace
No Relationships to Disclose
 
Jan Fagerberg
Employment - Enterome
Leadership - Enterome
Stock and Other Ownership Interests - Enterome
Travel, Accommodations, Expenses - Enterome
 
Joao Magalhaes
Employment - Enterome
Patents, Royalties, Other Intellectual Property - Enterome
 
Philippe Armand
Honoraria - Merck
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca; Bristol-Myers Squibb; C4 Therapeutics; Celgene; Enterome; Epizyme; Genentech/Roche; GenMab; Merck Sharp & Dohme; Regeneron; Tessa Therapeutics
Research Funding - Adaptive Biotechnologies (Inst); Affimed Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); igm (Inst); Kite, a Gilead company (Inst); Merck Sharp & Dohme (Inst); Roche (Inst)